Gilead Sciences
GILD
1,776 hedge funds and large institutions have $86.3B invested in Gilead Sciences in 2023 Q4 according to their latest regulatory filings, with 223 funds opening new positions, 652 increasing their positions, 696 reducing their positions, and 100 closing their positions.
123% more first-time investments, than exits
New positions opened: 223 | Existing positions closed: 100
11% more capital invested
Capital invested by funds: $78.1B → $86.3B (+$8.2B)
6% more funds holding
Funds holding: 1,682 → 1,776 (+94)
1.96% more ownership
Funds ownership: 83.47% → 85.43% (+2%)
6% less repeat investments, than reductions
Existing positions increased: 652 | Existing positions reduced: 696
9% less call options, than puts
Call options by funds: $819M | Put options by funds: $902M
23% less funds holding in top 10
Funds holding in top 10: 31 → 24 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.45B |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$262M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$183M |
| 4 |
Neuberger Berman Group
New York
|
+$172M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$148M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$266M |
| 2 |
Two Sigma Advisers
New York
|
-$198M |
| 3 |
Two Sigma Investments
New York
|
-$190M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$164M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$143M |
GILD Hedge Fund Activity: Q4 2023 in Review
1,776 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2023, worth a combined $86.3B — up 11% from $78.1B a quarter earlier.
Buyers outnumbered sellers: 223 funds opened new GILD positions and 100 closed out — a net gain of 123 holders — while 652 added to existing stakes and 696 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.45B. The largest seller was BlackRock, cutting an estimated $266M.
- 1,776 institutional investors held Gilead Sciences (GILD) as of Q4 2023, up from 1,682 in Q3 2023.
- Funds reported $86.3B of Gilead Sciences stock for Q4 2023, up 11% quarter-over-quarter.
- 223 funds opened new Gilead Sciences positions in Q4 2023 and 100 closed out, a net change of +123 holders.
- The largest Gilead Sciences buyer in Q4 2023 was Morgan Stanley, an estimated $1.45B added.
- The largest Gilead Sciences seller in Q4 2023 was BlackRock, an estimated $266M sold.
Based on aggregated 13F filings for Q4 2023.